Evidence map›Paper›PMID 42144519›Full record

ReviewCancer treatment and research2026

Glutamine Metabolism: Role in Cancer Cell Proliferation and Survival.

Aganta Chakraborty, Sanket Pramanik, Shrabasti Mullick, Rajarshi Nath, Mohini Mondal, Radheshyam Pal, Sumel Ashique, Mayukh Jana

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer treatment and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aganta ChakrabortyDepartment of Pharmaceutical Technology, Bharat Technology, Uluberia, West Bengal, India.
Sanket PramanikDepartment of Pharmaceutical Technology, Bharat Technology, Uluberia, West Bengal, India.
Shrabasti MullickDepartment of Pharmaceutical Technology, Bharat Technology, Uluberia, West Bengal, India.
Rajarshi NathDepartment of Pharmaceutical Technology, Bharat Technology, Uluberia, West Bengal, India.
Mohini MondalDepartment of Pharmaceutical Technology, Bharat Technology, Uluberia, West Bengal, India.
Radheshyam PalDepartment of Pharmacology, Bengal College of Pharmaceutical Technology, Dubrajpur, West Bengal, India.
Sumel AshiqueDepartment of Pharmaceutical Technology, Bharat Technology, Uluberia, West Bengal, India.ORCID https://orcid.org/0000-0003-4362-2830
Mayukh JanaDepartment of Pharmaceutical Technology, Bharat Technology, Uluberia, West Bengal, India.ORCID https://orcid.org/0009-0005-6385-2758

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glutamine is crucial for cancer cell proliferation and survival because it fuels the TCA cycle, provides building blocks for macromolecules, and helps maintain redox balance by supporting antioxidant pathways like glutathione production. Cancer cells often become dependent on glutamine, a phenomenon known as glutaminolysis, and use it to produce energy and essential molecules for rapid growth. This metabolic addiction makes glutamine metabolism a significant target for cancer therapies. In recent years, some therapeutic drugs targeting glutamine metabolism to treat cancer have been developed. However, such drugs are not sufficiently effective. Targeting metabolic reprogramming may be an effective strategy to enhance cancer treatment efficacy. Glutamine serves as a vital nutrient for cancer cells. Inhibiting glutamine metabolism has shown promise in preventing tumor growth both in vivo and in vitro through various mechanisms.

Indexed as

GlutamineNeoplasmsAnimalsCell ProliferationCell SurvivalCitric Acid CycleHumansMetabolic ReprogrammingGlutamineCancer microenvironmentGlutamine metabolismRedox balanceSignaling pathwaysTCA cycleTherapeutic targetsTumor proliferation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.